Bio-Quant Adds Dr. Roberto Crea to the Board.

SAN DIEGO -- Bio-Quant, Inc. ("Bio-Quant") the largest biotech Contract Research Organization (CRO) in San Diego, announced today the addition of Dr. Roberto Crea, one of the scientific co-founders of Genetech, to the board of directors. Dr. Crea replaces Mr. John Ryan. We are very grateful for Mr. Ryan's service over the past several years. This brings the number of board members to 5, of whom 2 are independent.

Dr. Crea has over 30 years of experience in the biotechnology field as a scientist, investor and entrepreneur. He is one of the scientific co-founders of Genetech, founder of Creative Bio Molecules, Inc. (1982), Creagen, Inc. (1992), CreAgri (1998), Bioren (2002) and ProtElix (2005). Creagen, Inc. was merged into Neurex in 1994, which was then sold to Elan Pharmaceuticals for over $700 million. Pfizer successfully acquired Bioren in 2005.

Dr. Crea received his Ph.D. in Biological Chemistry from University of Pavia, Italy. He was also an Associate Professor of DNA Chemical Synthesis at Leiden University in the Netherlands prior to moving to the US in 1977. Dr. Crea is the author of more than 25 international patents and has co-authored more than 50 scientific articles. He was also the recipient of the Rumbaugh Award for Scientific Contribution given by the Juvenile Diabetes Foundation for America.

"We are very pleased to have someone of Dr. Crea's stature joining the board of Bio-Quant. Dr. Crea not only brings the highest level of scientific credibility to the company, but also is an extremely successful businessman and entrepreneur whose experience and skill brings a great deal to Bio-Quant," said CEO Dr. Bassam Damaj.

About Bio-Quant, Inc.

Bio-Quant, Inc. is a profitable revenue-generating biotechnology pre-clinical contract research organization specializing in in vitro and in vivo pharmacology, PK and toxicology to support non-GLP pre-IND enabling studies in addition to vivarium housing services. The company is based in San Diego, California and has over 30 employees and 20,000 sq ft office and laboratory facilities. The company specializes in pre-clinical work in the areas of Inflammation, Oncology, and Immunology, PK and toxicology services.

More information is available at www.bio-quant.com

When used anywhere in this document, the words "expects," "believes," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating results of Bio-Quant and the timing, benefits and other aspects of the proposed merger. Bio-Quant has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Bio-Quant's strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues.

These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Bio-Quant disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.